The tragedy of translation: The case of "First use" in human embryonic stem cell research

Jan Helge Solbakk; Laurie Zoloth

doi:10.1016/j.stem.2011.04.009

The tragedy of translation: The case of "First use" in human embryonic stem cell research

Jan Helge Solbakk, Laurie Zoloth

Religious Studies

Research output: Contribution to journal › Comment/debate › peer-review

29 Scopus citations

Abstract

Who should go first in phase-I human trials when neither risks nor benefits can be estimated? By assessing concerns raised by Bretzner et al. (2011), we highlight a tragic dimension underlying all such trials. We discuss strategies to avoid the pitfalls of ethical hubris by promoting fidelity and trust.

Original language	English (US)
Pages (from-to)	479-481
Number of pages	3
Journal	Cell stem cell
Volume	8
Issue number	5
DOIs	https://doi.org/10.1016/j.stem.2011.04.009
State	Published - May 6 2011

ASJC Scopus subject areas

Molecular Medicine
Genetics
Cell Biology

Access to Document

10.1016/j.stem.2011.04.009

Cite this

@article{c709b6104bd143ce8b072d9ed45d47e3,

title = "The tragedy of translation: The case of {"}First use{"} in human embryonic stem cell research",

abstract = "Who should go first in phase-I human trials when neither risks nor benefits can be estimated? By assessing concerns raised by Bretzner et al. (2011), we highlight a tragic dimension underlying all such trials. We discuss strategies to avoid the pitfalls of ethical hubris by promoting fidelity and trust.",

author = "Solbakk, {Jan Helge} and Laurie Zoloth",

year = "2011",

month = may,

day = "6",

doi = "10.1016/j.stem.2011.04.009",

language = "English (US)",

volume = "8",

pages = "479--481",

journal = "Cell stem cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - The tragedy of translation

T2 - The case of "First use" in human embryonic stem cell research

AU - Solbakk, Jan Helge

AU - Zoloth, Laurie

PY - 2011/5/6

Y1 - 2011/5/6

N2 - Who should go first in phase-I human trials when neither risks nor benefits can be estimated? By assessing concerns raised by Bretzner et al. (2011), we highlight a tragic dimension underlying all such trials. We discuss strategies to avoid the pitfalls of ethical hubris by promoting fidelity and trust.

AB - Who should go first in phase-I human trials when neither risks nor benefits can be estimated? By assessing concerns raised by Bretzner et al. (2011), we highlight a tragic dimension underlying all such trials. We discuss strategies to avoid the pitfalls of ethical hubris by promoting fidelity and trust.

UR - http://www.scopus.com/inward/record.url?scp=79955676993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955676993&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2011.04.009

DO - 10.1016/j.stem.2011.04.009

M3 - Comment/debate

C2 - 21549323

AN - SCOPUS:79955676993

SN - 1934-5909

VL - 8

SP - 479

EP - 481

JO - Cell stem cell

JF - Cell stem cell

IS - 5

ER -

The tragedy of translation: The case of "First use" in human embryonic stem cell research

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this